| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd95a181ff623472c64fa16473fbad96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_471de79e617567083b3ac79ee45a51b7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 |
| filingDate |
2005-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2efe529855da9aa8767d00054f7aa3bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bed4d59a9f4e276d9a7477ff12d4853 |
| publicationDate |
2010-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7691831-B2 |
| titleOfInvention |
Pharmaceutical combination and method for treatment of reactive arthritis or bursitis |
| abstract |
A method for treatment for conditions in human beings associated with either or both reactive arthritis or bursitis comprising administering a combination of a member from each of the following groups of medications: (1) synthetic purine nucleoside analog antiviral drugs, (2) antibiotic drugs, and (3) imidazole drugs. Alternate embodiments of the invention include dual combinations of (A) a member of the synthetic purine nucleoside analog group of antiviral drugs and a member of the antibiotic group of drugs, (B) a member of the antibiotic group of drugs and a member of the imidazole family of drugs, and (C) a member of the synthetic purine nucleoside analog group of antiviral drugs and a member of the imidazole group of drugs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11020377-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11324721-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10682338-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11000507-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11000508-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10849884-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10857133-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10335390-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11602522-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9700574-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014080778-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11253501-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11684607-B2 |
| priorityDate |
1999-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |